Frazier Life Sciences Public Fund, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO)

Filing manager
Frazier Life Sciences Public Fund, L.P.
Reporting owner
Frazier Life Sciences Public Fund, L.P.
Security
Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share
Beneficially owned shares
3,698,271 shares
Ownership signal 2 signals
Class ownership
5.1%
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

5.1%

Beneficial ownership of this reported class.

Shares

3,698,271 shares

Shares beneficially owned as disclosed.

Event date

31 Dec 2025

Date tied to the ownership event or amendment.

Accepted by SEC

13 Feb 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security 2 source fields
Symbol
LXEO
Shares outstanding
72,515,118 shares
Source evidence 5 source fields
Form type
SCHEDULE 13G/A
Accepted by SEC
13 Feb 2026, 17:33:55 UTC
Event date
31 Dec 2025
Previous filing
14 Aug 2025
SEC filing
View on sec.gov

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 5.1% ownership in Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO) on 31 Dec 2025.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO).
  • Disclosed ownership: 5.1%.
  • Date of event: 31 Dec 2025.

Change

  • Previous schedule filing date: 14 Aug 2025.
  • Current filing was accepted on 13 Feb 2026, 17:33.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Disclosed reporting parties (14)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 5.1% 3,698,271 0 3,698,271 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 5.1% 3,698,271 0 3,698,271 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 5.1% 3,698,271 0 3,698,271 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. 0.1% 87,424 0 87,424 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.1% 87,424 0 87,424 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.1% 87,424 0 87,424 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.3% 232,784 0 232,784 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.3% 232,784 0 232,784 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.3% 232,784 0 232,784 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. 0.6% 406,246 0 406,246 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
FHMLS XII, L.P. 0.6% 406,246 0 406,246 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
FHMLS XII, L.L.C. 0.6% 406,246 0 406,246 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C.
James N. Topper 0.1% 87,424 0 87,424 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Patrick J. Heron 0.1% 87,424 0 87,424 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .